![](/img/cover-not-exists.png)
JAK2V617F allele burden ≥50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy
Barosi, G, Klersy, C, Villani, L, Bonetti, E, Catarsi, P, Poletto, V, Campanelli, R, Impera, S, Latagliata, R, Viarengo, G, Carolei, A, Massa, M, Musso, M, Crescimanno, A, Gale, R P, Rosti, VLanguage:
english
Journal:
Leukemia
DOI:
10.1038/leu.2016.45
Date:
February, 2016
File:
PDF, 820 KB
english, 2016